37904-72-6

Basic information

• Product Name: 2-BROMO-1-(4-DIMETHYLAMINO-PHENYL)-ETHANONE
• Synonyms: BUTTPARK 82\50-86;2-BROMO-4'-DIMETHYLAMINOACETOPHENONE;2-BROMO-1-(4-DIMETHYLAMINO-PHENYL)-ETHANONE;4-(Dimethylamino)phenacyl bromide;4-(Dimethylamino)phenacyl bromide 97%;2-Bromo-4'-(dimethylamino)acetophenone, 2-Bromo-1-[4-(dimethylamino)phenyl]ethan-1-one;2-BroMo-1-[4-(diMethylaMino)phenyl]ethan-1-one;4-(Dimethylamino)phenacylbromide97%
• CAS NO: 37904-72-6
• Molecular Formula: C₁₀H₁₂BrNO
• Molecular Weight: 242.11
• Product Categories: blocks;Bromides
• Mol File: 37904-72-6.mol

Chemical Properties

• Melting Point: 89-92
• Boiling Point: 330.2 °C at 760 mmHg
• Flash Point: 153.5 °C
• Appearance: /
• Density: 1.406±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.000169mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: Keep Cold
• Solubility: Chloroform (Sparingly), DMSO (Slightly, Sonicated)
• PKA: 1.56±0.12(Predicted)
• CAS DataBase Reference: 2-BROMO-1-(4-DIMETHYLAMINO-PHENYL)-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(4-DIMETHYLAMINO-PHENYL)-ETHANONE(37904-72-6)
• EPA Substance Registry System: 2-BROMO-1-(4-DIMETHYLAMINO-PHENYL)-ETHANONE(37904-72-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 37904-72-6(Hazardous Substances Data)

Usage

Uses

Used in Medical Research:
2-BROMO-1-(4-DIMETHYLAMINO-PHENYL)-ETHANONE is used as a potential biomarker for respiratory illnesses. Its presence in biological samples can indicate the presence or severity of certain respiratory conditions, aiding in diagnosis and treatment planning.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-BROMO-1-(4-DIMETHYLAMINO-PHENYL)-ETHANONE can be utilized as a key intermediate in the synthesis of various drugs targeting respiratory diseases. Its unique chemical structure allows for the development of novel therapeutic agents with improved efficacy and safety profiles.
Used in Chemical Research:
2-BROMO-1-(4-DIMETHYLAMINO-PHENYL)-ETHANONE can also be employed in chemical research as a starting material for the synthesis of other organic compounds with potential applications in various industries, such as materials science, agrochemicals, and environmental science.

InChI:InChI=1/C10H12BrNO/c1-12(2)9-5-3-8(4-6-9)10(13)7-11/h3-6H,7H2,1-2H3

Upstream product

• 2124-31-4 4'-dimethylaminoacetophenone 
• 210832-81-8 2,2-dibromo-1-(4-(dimethylamino)phenyl)ethan-1-one 

Downstream Products

• 474012-67-4 4-(6-bromo-imidazo[1,2-a]pyridin-2-yl)-N,N-dimethylbenzenamine 
• 1009734-00-2 C₂₁H₂₀N₆S 
• 1220909-57-8 C₁₄H₁₃ClN₄ 
• 1220909-58-9 C₁₄H₁₃IN₄ 
• 1220909-56-7 C₁₄H₁₃FN₄ 
• 1404113-20-7 2-(4-(dimethylamino)phenyl)-2-oxoethyl 2-(tert-butoxycarbonylamino)acetate 
• 1580490-38-5 C₁₃H₁₅N₃S 
• 1580490-42-1 C₁₉H₁₉N₃S 
• 1584133-21-0 4-(6-((tert-butyldimethylsilyl)oxy)quinoxalin-2-yl)-N,N-dimethylaniline 
• 1437281-35-0 4-(6-(2-fluoroethoxy)quinoxalin-2-yl)-N,N-dimethylaniline 
• 16032-41-0 2-(4-(dimethylamino)phenyl)quinoline 
• 1612226-13-7 1-(4-(dimethylamino)phenyl)-2-((trifluoromethyl)thio)ethanone 

Relevant articles and documents

Identification and characterization of benzo[d]oxazol-2(3H)-one derivatives as the first potent and selective small-molecule inhibitors of chromodomain protein CDYL

Chemical probes of epigenetic ‘readers’ of histone post-translational modifications (PTMs) have become powerful tools for mechanistic and functional studies of their target proteins in physiology and pathology. However, only limited ‘reader’ probes have been developed, which restricted our understanding towards these macromolecules and their roles in cells or animals. Here, we reported a structure-guided approach to develop and characterize benzo [d]oxazol-2(3H)-one analogs as the first potent and selective small-molecule inhibitors of chromodomain Y-like (CDYL), a histone methyllysine reader protein. The binding conformation between the chromodomain of CDYL and the modified peptidomimetics was studied via molecular docking and dynamic simulations, facilitating subsequent virtual screening of tens of hits from Specs chemical library validated by SPR technique (KD values: from 271.1 μM to 5.4 μM). Further design and synthesis of 43 compounds helped to interpret the structure-activity relationship (SAR) that lead to the discovery of novel small-molecule inhibitors of CDYL. Compound D03 (KD: 0.5 μM) was discovered and showed excellent selectivity among other chromodomain proteins, including CDYL2 (>140 folds), CDY1 (no observed binding) and CBX7 (>32 folds). Moreover, we demonstrated that D03 engaged with endogenous CDYL in a dose-dependent manner, and perturbed the recruitment of CDYL onto chromatin, resulting in transcriptional derepression of its target genes. Finally, the results showed that D03 promoted the development and branching of neurodendrites by inhibiting CDYL in hippocampal and cortical cultured neurons. This study not only discovers the first selective small-molecule inhibitors of CDYL, but provids a new chemical tool to intervene the dynamic nature of bio-macromolecules involved in epigenetic mechanism.

N,O π-Conjugated 4-Substituted 1,3-Thiazole BF2 Complexes: Synthesis and Photophysical Properties

A series of 1,3-thiazole-based organoboron complexes has been designed and synthesized by acylation of 2-amino 4-subsituted 1,3-thiazoles with (4-dimethylamino)benzoyl chloride and the subsequent BF2 complexation reaction. The influence of substituents in position 4 of the thiazole ring on photophysical properties of the complexes has been investigated. Synthesized thiazolo[3,2-c][1,3,5,2]oxadiazaborinines mainly showed intensive fluorescence in solutions. Complex with a 4,5-unsubstituted thiazole unit demonstrated an aggregation induced emission (AIE) effect and a very high fluorescent quantum yield (94%) in the solid state because of the inhibition of π-π/π-n interactions in the molecular packing.

Radiosynthesis of SPECT tracers: Via a copper mediated 123I iodination of (hetero)aryl boron reagents

A general method for the copper mediated nucleophilic 123I-iodination of (hetero)aryl boronic esters and acids has been developed. The broad substrate scope of this radiosynthetic approach allows access to [123I]DPA-713, [123I]IMPY, [123I]MIBG and [123I]IPEB that are four commonly used SPECT radiotracers. Our results infer that aryl boronic reagents can now be employed as common precursors for both fluorine-18 and iodine-123 radiolabelling.

Enantioselective synthesis of 2,3-disubstituted: Trans -2,3-dihydrobenzofurans using a Br?nsted base/thiourea bifunctional catalyst

The diastereo- and enantioselective synthesis of 2,3-disubstituted trans-2,3-dihydrobenzofuran derivatives (15 examples, up to 96 : 4 dr, 95 : 5 er) via intramolecular Michael addition has been developed using keto-enone substrates and a bifunctional tertiary amine-thiourea catalyst. This methodology was extended to include non-activated ketone pro-nucleophiles for the synthesis of 2,3-disubstituted indane and 3,4-disubstituted tetrahydrofuran derivatives.

INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

RADIOACTIVE FLUORINE-LABELED QUINOXALINE COMPOUND

Provided is a compound effective as a diagnostic imaging probe targeting amyloid and an agent for Alzheimer's disease diagnosis including the compound.

Structure-activity relationships and in vivo evaluation of quinoxaline derivatives for PET imaging of β-amyloid plaques

This letter describes the synthesis, structure-activity relationships, and in vivo evaluation of a new series of 2-phenylquinoxaline (PQ) derivatives for imaging β-amyloid (Aβ) plaques in Alzheimer's disease (AD). In experiments in vitro, the affinity of

COMPOSITIONS AND METHODS FOR THE TREATMENT AND ANALYSIS OF NEUROLOGICAL DISORDERS

Provided herein are compositions and methods for the treatment and analysis of neurological disorders. In particular, provided herein are small molecules targeted to amyloid-β (Aβ ) or metal-Aβ species for the treatment, diagnosis, or study of neurological conditions such as Alzheimer's disease (AD) and other diseases and conditions.

2-Arylimidazo[2,1-b]benzothiazoles: A new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain

We designed and synthesized a small series of 2-aryl-imidazo[2,1-b] benzothiazole, representing a combination of motifs from the two most potent amyloid imaging agents, PIB and IMPY. The binding affinity of the new compounds ranged from 6 to 133 nM. Among the best compounds, 3b (Ki = 6 nM) can be labeled with 11CH3 for PET imaging whereas 3j (K i = 10.9 nM) can be labeled with 123I for SPECT imaging.

Novel quinoxaline derivatives for in vivo imaging of β-amyloid plaques in the brain

In a search for new probes to detect β-amyloid plaques in the brain of patients with Alzheimer's disease (AD), we have synthesized and evaluated a series of quinoxaline derivatives containing a '6+6-6' ring system. These quinoxaline derivatives showed excellent affinity for Aβ1-42 aggregates with Ki values ranging from 2.6 to 10.7 nM. Autoradiography with sections of brain tissue from an animal model of AD mice (APP/PS1) and AD patients revealed that [125I]5 labeled β-amyloid plaques specifically. In biodistribution experiments using normal mice, [125I]5 displayed high uptake (6.03% ID/g at 2 min) into and a moderately fast washout from the brain. Although additional refinements are needed to decrease the lipophilicity and improve the washout rate, the quinoxaline scaffold may be useful as a backbone structure to develop novel β-amyloid imaging agents.